Previous 10 | Next 10 |
home / stock / orxoy / orxoy news
UPPSALA, Sweden , March 12, 2020 /PRNewswire/ -- As previously communicated, Orexo invites investors, analysts and the media to participate in the company's Capital Markets Day in Stockholm, Sweden , on March 17 , at Helio GT30, Grev Turegatan 30. Due to the ongoing COVID-19 outbreak...
vorvida ® clearance from FDA anticipated Q2 2020 Expects to launch its first digital therapy in the US for heavy alcohol use in H2 2020 UPPSALA, Sweden , March 6, 2020 /PRNewswire/ -- Orexo AB (publ), today announces it has submitted an application to the US Food ...
UPPSALA, Sweden , Feb. 19, 2020 /PRNewswire/ -- Orexo AB (publ.), today invites investors, analysts and media to attend the company's Capital Markets Day, taking place in Stockholm, Sweden , on March 17 , at Helio GT30, Grev Turegatan 30. Members of Orexo's management team, including ...
UPPSALA, Sweden , Feb. 17, 2020 /PRNewswire/ -- The board of Orexo AB (publ.) has resolved, pursuant to the authorisation granted by the annual general meeting held on 11 April 2019 , to initiate a repurchase program of ordinary shares. The repurchases may comprise a maximum of 500,...
UPPSALA, Sweden , Jan. 30, 2020 /PRNewswire/ -- Q4 2019 highlights Total net revenues of SEK 238.1 million (227.1), up 4.8 percent Zubsolv®...
OX338 demonstrated improved bioavailability and tolerability compared to commercially available reference product Further work required to optimise product formulation UPPSALA, Sweden , Jan. 29, 2020 /PRNewswire/ -- Orexo AB (publ.) today announces promising results from it...
UPPSALA, Sweden , Dec. 3, 2019 /PRNewswire/ -- Orexo AB (publ.), the fully integrated specialty pharmaceutical company with the aim of becoming a leader in the treatment of addiction, today announces that the company will host a Capital Markets Day for investors, analysts and media in St...
- Appointment strengthens Orexo's competencies and resources within digital health - Orexo committed to finding innovative solutions to improve treatment of addiction UPPSALA, Sweden , Dec. 2, 2019 /PRNewswire/ -- Orexo AB (publ), the fully integrated specialty pharmaceutical ...
UPPSALA, Sweden , Nov. 27, 2019 /PRNewswire/ -- Orexo AB (publ), the fully integrated specialty pharmaceutical company with the aim of becoming a leader within treatment of addiction, today announces it has acquired the exclusive US rights to vorvida®, a digital therapy for the treat...
The following slide deck was published by Orexo AB (publ) in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
Orexo Q2 2024 Interim Report PR Newswire UPPSALA, Sweden , July 17, 2024 /PRNewswire/ -- Making progress, while the OX124 review time extended Q2 2024 highlights Total net revenues of SEK 154.0 m (157.7) EBITDA of SEK 5.0 m (5.6)...
Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose PR Newswire UPPSALA, Sweden , July 16, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that the company has received...
Orexo AB´s sustainability work ranked among top 5% by EcoVadis PR Newswire UPPSALA, Sweden , July 10, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) announces that it has received a Gold Sustainability Rating by EcoVadis, one of the...